A Phase I Clinical Trial of Human CD19 Targeted T Cells Injection for Subjects With Relapsed and Refractory CD19-positive Diffuse Large B-cell Lymphoma and Follicular Lymphoma
Latest Information Update: 19 Oct 2024
At a glance
- Drugs HR 001 (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions
- Sponsors Hrain Biotechnology
- 26 Oct 2018 Status changed from not yet recruiting to recruiting.
- 14 Aug 2018 New trial record